USO 25227

A PHASE 2/3 INTERVENTIONAL STUDY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY IN TREATMENT-NAÏVE PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC GASTRIC, GASTROESOPHAGEAL JUNCTION, OR ESOPHAGEAL ADENOCARCINOMA: C6461016

Disease Types: Gastrointestinal Cancer Research

Eligibility Requirements:

• Histologically or cytologically confirmed gastric, GEJ, or
esophageal adenocarcinoma that is locally advanced unresectable
or metastatic
• No prior systemic therapy for advanced or metastatic disease
• Subjects should have PD-L1 tumor expression (TAP ≥1% or CPS
≥1) and HER2-negative status based on local testing results
• Subjects with squamous cell or undifferentiated gastroesophageal
cancer are excluded
• Subjects with prior exposure to anti-VEGF therapy or cancer
immunotherapy, including but not limited to anti-PD-1/PD-L1
therapy are excluded.

For more information on this trial CLICK HERE .

Available at:

• Chesapeake
• Hampton (CarePlex)
• Newport News (Port Warwick III)
• Virginia Beach (Princess Anne)
• Norfolk (Brock Cancer Center)